Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Niraparib’s Indication Expands in Ovarian Cancer

June 19th 2020

Bhavana Pothuri, MD, discusses the practice-changing implications of niraparib’s approval in ovarian cancer.

Dr. Matulonis on Final Data From KEYNOTE-100 in Recurrent Ovarian Cancer

June 11th 2020

Ursula A. Matulonis, MD, discusses final data from the phase 2 KEYNOTE-100 trial with pembrolizumab (Keytruda) in advanced recurrent ovarian cancer.

Dr. Swisher on the Phase III VELIA Results in Ovarian Cancer

June 7th 2020

Elizabeth M. Swisher, MD, discusses results from the phase III VELIA/GOG-3005 trial in ovarian cancer.

Dr. Zakashansky on the Benefit of Maintenance Olaparib in BRCA+ Ovarian Cancer

June 3rd 2020

Konstantin Zakashansky, MD, discusses final overall survival data from the phase 3 SOLO2 trial evaluating maintenance olaparib (Lynparza) in platinum-sensitive, relapsed ovarian cancer with a BRCA mutation.

Dr. Poveda on the Results of the SOLO2 Trial in Ovarian Cancer

June 2nd 2020

Andres Poveda, MD, discusses the results of the phase 3 SOLO2 trial in advanced ovarian cancer.

Updated AVANOVA2 Survival Data Further Support Niraparib Plus Bevacizumab in Recurrent Ovarian Cancer

May 30th 2020

Clinical outcomes in patients with recurrent ovarian cancer who were treated with niraparib plus bevacizumab were significantly improved when compared with niraparib alone.

Mirvetuximab Soravtansine Combination Shows Positive Response, Tolerability in Ovarian Cancer

May 30th 2020

Mirvetuximab soravtansine in combination with bevacizumab to treat patients with platinum-agnostic ovarian cancer demonstrated encouraging overall response rates regardless of platinum status with a favorable tolerability profile.

Cediranib/Olaparib Combo Yields Comparable Results to Chemo in Ovarian Cancer Treatment

May 29th 2020

A phase III study using cediranib and olaparib to treat recurrent platinum-sensitive ovarian cancer did not meet its primary endpoint of progression-free survival but did produce comparable activity to standard of care platinum-based chemotherapy treatment.

Maintenance Niraparib Boosts PFS in Phase 3 Study of Chinese Patients With Ovarian Cancer

May 29th 2020

Maintenance niraparib improved progression-free survival in Chinese patients with recurrent ovarian cancer who were in a complete or partial response to platinum-based chemotherapy, meeting the primary end point of the phase 3 NORA study.

Systemic Management of Ovarian Cancer: Closing Thoughts

May 27th 2020

Novel Combination Strategies in Recurrent Ovarian Cancer

May 27th 2020

Recurrent Ovarian Cancer: Novel Agents Under Investigation

May 27th 2020

Bevacizumab’s Role in Recurrent Ovarian Cancer

May 27th 2020

Recurrent Ovarian Cancer: Choosing a PARP Inhibitor

May 27th 2020

PARP Inhibition’s Role in Recurrent Ovarian Cancer

May 27th 2020

Frontline Ovarian Cancer Management: Ongoing Clinical Trials

May 27th 2020

Considerations for the JAVELIN OVARIAN 100 Study

May 27th 2020

Ovarian Cancer: Maintenance Following Frontline Bevacizumab

May 27th 2020

Ovarian Cancer: Updates to NCCN Guidelines

May 27th 2020

Treating Ovarian Cancer Based on HRD Status

May 27th 2020